Related Experiment Video
Updated: Aug 31, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
Optimization of functional efficacy of phosphorothioate-modified oligonucleotides in a human CD8+ T-cell ex vivo
N A Al-Shanti1, C G Steward, R J Garland
1University of Bristol, Department of Pathology and Microbiology, University Walk, UK.
Abstract:
Antisense oligodeoxyribonucleotides (ODNs) can specifically inhibit gene expression, but their application to fresh human CD8+ T cells is limited by poor spontaneous uptake (<2%). We have examined and optimized the uptake of phosphorothioate-modified oligodeoxyribonucleotides (PS-ODNs) into these cells in an ex vivo expansion model. Optimal antisense treatments were found to be, for fresh CD8+ T cells, 1 micro m PS-ODNs complexed with lipofectin (LF), which resulted in 35% uptake and 10 micro m PS-ODNs in the absence of LF, for cultured cells, which resulted in 95% uptake. The delivered antisenses were functional, as determined by the inhibition of protein expression. In this respect, partially phosphorothioate-modified ODNs (PS-ODNs-P) were twice as effective as completely modified (PS-ODNs-C), and the antisense specific for the cap site showed the highest protein suppression of those tested (68%). Uptake mechanisms were also investigated. To our knowledge, this is the first optimization of the delivery of antisense oligonucleotides into human CD8+ T cells. This protocol could be used to study the function of a particular gene in cytotoxic T lymphocytes and also by those looking for a method to deliver short interfering RNA into cell lines to specifically suppress a gene of interest.
Insights
Optimizing antisense oligodeoxyribonucleotides (ODNs) delivery into human CD8+ T cells enhances gene silencing. This study presents a novel protocol for efficient delivery, crucial for T cell research and gene suppression applications.
Area of Science:
- Immunology
- Molecular Biology
- Gene Therapy
Background:
- Antisense oligodeoxyribonucleotides (ODNs) offer specific gene expression inhibition.
- Poor spontaneous uptake (<2%) limits ODN application in fresh human CD8+ T cells.
- Ex vivo expansion models are essential for optimizing T cell-based therapies.
Purpose of the Study:
- To optimize the delivery and uptake of phosphorothioate-modified oligodeoxyribonucleotides (PS-ODNs) into fresh and cultured human CD8+ T cells.
- To evaluate the functionality and efficacy of delivered antisense ODNs in inhibiting protein expression.
- To investigate the mechanisms underlying ODN uptake in CD8+ T cells.
Main Methods:
- Optimization of PS-ODN concentration and lipofectin (LF) complexation for fresh CD8+ T cells (1 µM PS-ODNs with LF).
- Optimization for cultured CD8+ T cells (10 µM PS-ODNs without LF).
- Assessment of antisense functionality via protein expression inhibition and comparison of different ODN modifications (partially vs. completely phosphorothioate-modified).
Main Results:
- Achieved 35% uptake in fresh CD8+ T cells using 1 µM PS-ODNs with LF.
- Achieved 95% uptake in cultured CD8+ T cells using 10 µM PS-ODNs without LF.
- Partially modified PS-ODNs were twice as effective as fully modified ones, with cap site-specific antisense showing 68% protein suppression.
Conclusions:
- This study presents the first optimized protocol for delivering antisense oligonucleotides into human CD8+ T cells.
- The developed method significantly enhances ODN uptake and functional gene silencing in CD8+ T cells.
- This protocol can be applied to study gene function in cytotoxic T lymphocytes and for delivering short interfering RNA (siRNA) for gene suppression.
